Brickell Biotech Inc., of Miami, entered into a license agreement with Merz North America Inc., granting Merz, of Greensboro, N.C., an exclusive North American license, with certain additional international rights, to develop and commercialize a retinoid compound, BBI-3000, for the treatment of skin conditions known to be responsive to retinoid agents, such as acne and psoriasis.